Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical Cancer Research

• Publication date

  2003-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 12738717
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas

  2006cited by this paper
• Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches

  2004cited by this paper
• Role of the Tumor Microenvironment in Mediating Response to Anti-angiogenic Therapy

  2004cited by this paper
• The Controls of Microvascular Survival

  2004cited by this paper
• Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

  2002cited by this paper
• Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.

  2002cited by this paper
• A role for survivin in chemoresistance of endothelial cells mediated by VEGF

  2002cited by this paper
• Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.

  2002cited by this paper
• Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.

  2002cited by this paper
• Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.

  2001cited by this paper
• Venous thromboembolism and occult malignancy.

  2001cited by this paper
• Receptor Heterodimerization: Essential Mechanism for Platelet-Derived Growth Factor-Induced Epidermal Growth Factor Receptor Transactivation

  2001cited by this paper
• Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor.

  2001cited by this paper
• Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

  2000cited by this paper
• The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.

  2000cited by this paper
• Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.

  2000cited by this paper
• Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.

  2000cited by this paper
• Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.

  1999cited by this paper
• SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

  1999cited by this paper
• Molecular and biological properties of vascular endothelial growth factor

  1999cited by this paper
• Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.

  1999cited by this paper
• Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.

  1998cited by this paper
• Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites.

  1998cited by this paper
• VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts

  1998cited by this paper
• The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways*

  1997cited by this paper
• Enhanced expression of vascular endothelial growth factor in metastatic melanoma.

  1997cited by this paper
• Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma.

  1997cited by this paper
• Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma.

  1997cited by this paper
• Vascular endothelial growth factor expression is increased in renal cell carcinoma.

  1997cited by this paper
• The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity

  1997cited by this paper
• Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.

  1996cited by this paper
• Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.

  1996cited by this paper
• Patterns and Emerging Mechanisms Review of the Angiogenic Switch during Tumorigenesis

  1996influential reference
• Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis.

  1996cited by this paper

• Image-based modeling of vascular organization to evaluate anti-angiogenic therapy

  2023cites this paper
• To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors.

  2023cites this paper
• The development of 3-substituted indolin-2-one derivatives as kinase inhibitors for cancer therapy.

  2021cites this paper
• Dopamine agonists for preventing ovarian hyperstimulation syndrome.

  2021cites this paper
• Loss of Von Hippel–Lindau (VHL) Tumor Suppressor Gene Function: VHL–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC)

  2021cites this paper
• RTK Inhibitors in Melanoma: From Bench to Bedside

  2021cites this paper
• Integrative Clustering Reveals a Novel Subtype of Soft Tissue Sarcoma With Poor Prognosis

  2020cites this paper
• The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth inhibition by SU5416 in hepatoma cells

  2017cites this paper
• Determinants of treatment in patients with stage IV renal cell carcinoma

  2017cites this paper
• Pazopanib in the management of advanced soft tissue sarcomas

  2016cites this paper
• Dopamine agonists for preventing ovarian hyperstimulation syndrome.

  2016cites this paper
• Synthesis and Cytotoxic Activity of Self‐Assembling Squalene Conjugates of 3‐[(Pyrrol‐2‐yl)methylidene]‐2,3‐dihydro‐1H‐indol‐2‐one Anticancer Agents

  2015cites this paper
• Comparison of effects of anti-angiogenic agents in the zebrafish efficacy–toxicity model for translational anti-angiogenic drug discovery

  2014cites this paper
• Anti-angiogenic therapy, a new player in the field of sarcoma treatment.

  2014influential citation
• Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications

  2014cites this paper
• Role of pigment epithelium-derived factor in the reproductive system.

  2014cites this paper
• Local interaction between the dopaminergic system and the vascular endothelial growth factor and its type 2 receptor (VEGF/VEGFR2) in the regulation of corpus luteum angiogenesis in physiologic and pathologic conditions

  2014cites this paper
• PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

  2014cites this paper
• Grundlagen der systemischen Therapie

  2014cites this paper
• Targeting Angiogenesis for Treatment of Human Cancer

  2013cites this paper
• A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined with Weekly Cisplatin and Irinotecan in Patients with Advanced Solid Tumors

  2013cites this paper
• Cabergoline as treatment of ovarian hyperstimulation syndrome: a review

  2013cites this paper
• The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice.

  2013cites this paper
• The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

  2012influential citation
• Targeted Anti-Cancer Therapies for Renal Cancer

  2012cites this paper
• The role of angiogenesis inhibitors in the management of melanoma.

  2012cites this paper
• Etiology of OHSS and use of dopamine agonists.

  2012cites this paper
• EGFR, HER2 and VEGF Pathways

  2012cites this paper
• Molecular Biology for Urologists

  2011cites this paper
• Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.

  2011cites this paper
• Pharmacogenetics and Pharmacogenomics I: Linking Diagnostic Classification to Therapeutic Decisions

  2011cites this paper
• Cryoimmunology for malignant bone and soft-tissue tumors

  2011cites this paper
• Suppression of Soft Tissue Sarcoma Growth by a Host Defense-Like Lytic Peptide

  2011cites this paper
• Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.

  2011cites this paper
• Role of Angiogenesis and Microenvironment in Melanoma Progression

  2011cites this paper
• Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam

  2010cites this paper
• Targeting angiogenesis in melanoma: prospects for the future

  2010cites this paper
• From Melanocyte to Malignant Metastatic Melanoma

  2010cites this paper
• AETIOLOGY AND PHYSIOPATHOLOGY OF PREECLAMPSIA AND RELATED FORMS

  2010cites this paper
• TRAIL and Doxorubicin Combination Induces Proapoptotic and Antiangiogenic Effects in Soft Tissue Sarcoma In vivo

  2010cites this paper
• Angiogenesis and Progression in Human Melanoma

  2010cites this paper
• Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma

  2010cites this paper
• VEGF INHIBITORS FOR CANCER THERAPY

  2010cites this paper
• Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction

  2010cites this paper
• Physiology and Pathology of Ovarian Hyperstimulation Syndrome

  2010cites this paper
• Physiology and pathology of ovarian hyperstimulation syndrome.

  2010cites this paper
• Ultrasound and shockwave therapy for acute fractures in adults.

  2010cites this paper
• Non-invasive contrast enhanced ultrasound for quantitative assessment of tumor microcirculation. Contrast mixed mode examination vs. only contrast enhanced ultrasound examination

  2010cites this paper
• Vascular targeting tumor therapy: Non-invasive contrast enhanced ultrasound for quantitative assessment of tumor microcirculation

  2010cites this paper
• Prevention of OHSS – dopamine agonists

  2009cites this paper
• Symposium: Update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists.

  2009cites this paper
• Vascular complications of endothelium targeting therapies

  2009cites this paper
• Anti-angiogenic agents and cancer: current insights and future perspectives.

  2009cites this paper
• The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.

  2009cites this paper
• The dynamics of tumour–vasculature interaction suggests low‐dose, time‐dense anti‐angiogenic schedulings

  2009cites this paper
• Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy

  2009cites this paper
• Thrombosis associated with angiogenesis inhibitors.

  2009cites this paper
• Hemostatic complications of angiogenesis inhibitors in cancer patients

  2008cites this paper
• SELECTIVE TARGETING OF THE TUMOUR VASCULATURE *

  2008cites this paper
• Targeted therapy for advanced renal cell cancer: cytokines and beyond.

  2008cites this paper
• Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.

  2008cites this paper
• Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.

  2008cites this paper
• Non-steroidal targets in the diagnosis and treatment of endometriosis.

  2008cites this paper
• Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

  2008cites this paper
• Signal Transduction Inhibitors in Renal Cell Cancer

  2008cites this paper
• What is the risk of intracranial bleeding during anti-VEGF therapy?

  2008cites this paper
• Combined Vascular Endothelial Growth Factor Receptor/Epidermal Growth Factor Receptor Blockade with Chemotherapy for Treatment of Local, Uterine, and Metastatic Soft Tissue Sarcoma

  2008cites this paper
• Potential Combination Chemotherapy Approaches for Advanced Adult-Type Soft-Tissue Sarcoma

  2008cites this paper
• The von Hippel‐Lindau gene

  2008cites this paper
• Using molecular biology to develop drugs for renal cell carcinoma

  2008cites this paper
• Angiogenesis and Angiogenesis Inhibition in Sarcomas

  2008cites this paper
• Antiangiogenic Therapy of Renal Cell Carcinoma

  2008cites this paper
• Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance

  2008cites this paper
• Angiogenesis and antiangiogenic therapy in hematologic malignancies.

  2007cites this paper
• Anti-angiogenic therapy in the treatment of advanced renal cell cancer.

  2007cites this paper
• Chromosomes, Hypoxia, Angiogenesis, and Trial Design: A Brief History of Renal Cancer Drug Development

  2007cites this paper
• Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies.

  2007cites this paper
• Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.

  2007cites this paper
• Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?

  2007cites this paper
• EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.

  2007cites this paper
• Targeted therapies for soft-tissue sarcomas

  2007cites this paper
• Renal cell carcinoma

  2007cites this paper
• A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma

  2007cites this paper
• Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

  2007cites this paper
• Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.

  2007cites this paper
• Novel treatment strategies for soft tissue sarcoma.

  2007cites this paper
• Primary pulmonary artery sarcoma: report of three cases and review of the literature.

  2007cites this paper
• Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma.

  2007cites this paper
• Vascular endothelial growth factor (VEGF) inhibition--a critical review.

  2007cites this paper
• Alpha-v Integrins as Therapeutic Targets in Oncology

  2007cites this paper
• New drug therapies for advanced renal cell carcinoma

  2007cites this paper
• Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment.

  2007cites this paper
• Molecular design and clinical development of VEGFR kinase inhibitors.

  2007cites this paper
• Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS-Kaposi's sarcoma.

  2007cites this paper
• Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction

  2007cites this paper
• Src kinase inhibitors for the treatment of sarcomas: Cellular and molecular mechanisms of action

  2007cites this paper
• Grundlagen der systemischen Therapie

  2007cites this paper
• Protein Tyrosine Kinases as Targets for Cancer and Other Indications

  2006cites this paper
• Kinase inhibitors in the treatment of renal cell carcinoma.

  2006cites this paper
• Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

  2006cites this paper